Introduction
============

Patients with postherpetic neuralgia (PHN) suffer from persistent and severe breakthrough pain, which may arise from nerve changes due to virus infection or immune response.[@b1-jpr-11-1637] PHN results from injury to the nervous system caused by varicella zoster virus (VZV) during infection.[@b2-jpr-11-1637] PHN is one of the most common types of neuropathic pain (NP) syndrome and is characterized by pain.[@b3-jpr-11-1637] Patients who recover from herpes zoster rash may be afflicted with months and years of pain.[@b4-jpr-11-1637] Some studies have reported that compared with other types of pain, PHN is characterized by severe pain and severe harm to the patient's quality of life.[@b5-jpr-11-1637] In PHN, NP derived from previous VZV infection can last for 1--12 months,[@b6-jpr-11-1637] and some studies have reported that this pain can last for 3 months in 21% of patients, 6 months in 9% of patients, and 12 months in 6% of patients, despite early drug therapy.[@b7-jpr-11-1637],[@b8-jpr-11-1637] In recent years, the concept of PHN therapy has focused on systemic antiviral drug therapy as well as pain management and topical treatment.[@b9-jpr-11-1637]

Ozone is a molecule composed of three oxygen atoms and a component of the atmosphere in nature, which has a strong oxidizing action. Ozone has a high-energy, variable molecular structure under normal temperature and is quickly and spontaneously decomposed into O~2~ and a single oxygen atom (O). It has strong activity in oxidation and a strong bactericidal effect on bacteria and viruses.[@b10-jpr-11-1637],[@b11-jpr-11-1637] Ozone therapy inactivates bacteria by disrupting their cell envelope through oxidation of phospholipids and lipoproteins, inhibits fungi growth, damages the capsid of viruses, and upsets the reproductive cycle by disrupting the virus-to-cell contact with peroxidation.[@b12-jpr-11-1637] Oxygen-ozone therapy causes an increase in the rate of red blood cell glycolysis, causing the stimulation of 2,3-diphosphoglycerate, which leads to an increase in oxygen released to the tissues.[@b13-jpr-11-1637] It also causes a reduction in NADH and helps to oxidize cytochrome C.[@b14-jpr-11-1637] It increases the production of interferon, tumor necrosis factor, and interleukin-2, activating the immune system.[@b15-jpr-11-1637] Nowadays, the bactericidal effects of ozone therapy have been studied in detail and have been extensively reported in hepatitis B, diabetes mellitus, degenerative diseases, ischemic diseases, and so forth.[@b16-jpr-11-1637]--[@b18-jpr-11-1637] In addition, many studies have also reported on available scientific evidence concerning the beneficial properties of ozone therapy of pain, resulting in ozone therapy being widely used in pain management.[@b19-jpr-11-1637],[@b20-jpr-11-1637] However some complications of oxygen-ozone therapy still exist, such as headache pain, pneumocephalus, and cardiopulmonary arrest.[@b21-jpr-11-1637],[@b22-jpr-11-1637]

At present, the efficacy and safety of ozone autohemo-therapy in PHN remains unclear. Therefore, the objective of this study was to investigate the effectiveness and safety of ozone autohemotherapy combined with pharmacological therapy in patients with PHN.

Subjects and methods
====================

Study design, setting, and selection of patients
------------------------------------------------

A total of 120 patients with PHN were recruited from the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University from May 2015 to March 2017. According to the inclusion and exclusion criteria, 98 PHN patients were ultimately enrolled in this study. A random-number method using a computerized number generator (version 8.3; SAS Institute Inc., Cary, NC, USA) was used to randomly divide all included patients into the pharmacological therapy group and the ozone therapy group (49 patients in each group). The inclusion criteria were as follows: 1) PHN and suffering from severe pain for more than 1 month, 2) age \>18 years, 3) Visual Analog Scale (VAS) score \>4 points, and 4) ability to communicate in the language and follow the instructions. The exclusion criteria were as follows: 1) presence of other NP, 2) mental illness or central nervous system disease, and 3) malignant tumors. The enrolled patients signed written informed consent and this study was approved by the Medical Ethical Committee of Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan Province, People's Republic of China. The registration had been finished (No. researchregistry2767).

Therapeutic method
------------------

Patients in the pharmacological therapy group accepted pharmacological therapy for only 2 weeks, and the patients in the ozone autohemotherapy group were administered ozone autohemotherapy combined with pharmacological therapy for 2 weeks. The pharmacological therapy was performed with diclofenac 75 mg/day, pregabalin 300 mg/day, and cobama-mide 1 mg/day. Ozone autohemotherapy was performed as follows: In the morning, 200 mL blood was collected via the median cubital vein, the concentration of medical ozone was set as 30 μg/mL using an ozone medical apparatus (Green Environmental Protection Equipment Co., Ltd., Chengdu, Sichuan Province, China), 40 mL medical ozone was incubated in 200 mL autologous blood for 3--5 minutes, and the incubated blood was then transfused back into the patient within 15 minutes, three times per week, for 2 weeks.

Outcome measurements
--------------------

### VAS

The VAS was a 100-mm horizontal line labeled no pain at one end and worst imaginable pain at the other end. The patients were asked to mark on this line where the intensity of the pain existed. The distance from no pain to the patients' mark numerically quantifies the pain. The VAS is a simple and efficient method that correlates well with other reliable methods.

### McGill Pain Questionnaire (MPQ)

The MPQ has three parts: the first assesses pain quality and yields a sensory score (sum of 11 adjectives: throbbing, shooting, stabbing, sharp, cramping, gnawing, hot burning, aching, heavy, tender, and splitting, each rated on an intensity scale with 0= none, 1= mild, 2= moderate, and 3= severe), an affective score (sum of four adjectives, tiring-exhausting, sickening, fearful, and punishing-cruel related on the same intensity scale), and a total score (sum of the sensory and effective scores). The second part of the short form (SF)-MPQ consists of a 100-mm VAS of pain intensity that patients used to rate their pain during the preceding week. The third part of the SF-MPQ is a measure of present pain intensity (PPI) using a 6-point scale (0= none, 1= mild, 2= discomfort, 3= distressing, 4= horrible, and 5= excruciating).

### Patients' Global Impression of Change (PGIC)

The evaluation of relief level of pain symptoms was measured by the PGIC score. It is a 4-point numerical rating scale (1= obvious improvement, 2= slight improvement, 3= no change, 4= pain is more intense).

World Health Organization Quality of Life (WHOQOL-BREF)
-------------------------------------------------------

The evaluation of quality of life was measured using five selected items of the WHOQOL-BREF, which conveys good reliability and validity for the assessment of quality of life in individuals. Respondents are asked to rate their satisfaction with overall quality of life and four different life domains (ie, health, daily activities, relationships, and living conditions) on a 5-point response scale ranging from very dissatisfied to very satisfied. The higher scores indicate higher quality of life.

### Statistical analysis

All data were analyzed using SPSS 19.0 (IBM Corporation, Armonk, NY, USA) and GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). The data were presented as the mean ± SD or n (%). The independent-samples *t*-test was used for statistical analysis of the continuous data, and the Chi-squared test was used for statistical analysis of the categorical data. The repeated-measures analysis of variance (ANOVA) test was used to compare data between the two groups before and after treatment. A *P*-value \<0.05 was considered to represent a statistically significant difference.

Results
=======

A total of 120 PHN patients initially entered the study ([Figure 1](#f1-jpr-11-1637){ref-type="fig"}). Of these patients, 12 patients did not meet the inclusion criteria and 10 patients met the exclusion criteria. Therefore, 98 PHN patients were randomly divided into the pharmacological therapy group and the ozone autohe-motherapy group. There were four PHN patients who were lost to follow-up in the pharmacological therapy group and three PHN patients who were lost to follow-up in the ozone autohemotherapy group; therefore, 45 PHN patients were enrolled in the pharmacological therapy group and 46 PHN patients in the ozone autohemotherapy group, as shown in [Figure 1](#f1-jpr-11-1637){ref-type="fig"}. In addition, there were no statistically significant differences in the characteristics between groups at baseline (*P*\>0.05), as shown in [Table 1](#t1-jpr-11-1637){ref-type="table"}.

In this study, we examined the change in VAS score, the 50% VAS reduction of the initial value, and MPQ, PGIC, and WHOQOL-BREF scores from both groups before and after treatment. The results showed that compared with before therapy, there were significant improvements in the VAS, MPQ, PGIC, and WHOQOL-BREF scores after therapy (*P*\<0.05). Moreover, compared with the pharmacological therapy group, the scores of patients in the ozone autohemotherapy group were significantly improved in the VAS, MPQ, PGIC, and WHOQOL-BREF and in the 50% VAS reduction of the initial value after therapy (*P*\<0.05), as shown in [Tables 2](#t2-jpr-11-1637){ref-type="table"}[](#t3-jpr-11-1637){ref-type="table"}[](#t4-jpr-11-1637){ref-type="table"}[](#t5-jpr-11-1637){ref-type="table"}--[6](#t6-jpr-11-1637){ref-type="table"}.

Finally, in this study, we also observed adverse reactions, including nausea, vomiting, dizziness, somnolence, palpitations, chest tightness, bleeding, infection, and allergy, in both groups after treatment. The results showed that the adverse effects experienced in both groups were not statistically different after treatment, as shown in [Table 7](#t7-jpr-11-1637){ref-type="table"}.

Discussion
==========

PHN is a sequela of herpes zoster virus infection and is an NP. Age and duration of disease are potential risk factors.[@b23-jpr-11-1637] When herpes zoster infection is present, complications, especially PHN, can develop and are associated with substantial morbidity among elderly patients. For patients with herpes zoster, PHN is a common complication and affects the life quality of these patients.[@b24-jpr-11-1637] PHN is frequently accompanied by severe pain; however, the underlying mechanism of this complication remains unclear. In addition, until now, available therapy for PHN is still not ideal.

At present, clinical therapy of the disease consists of comprehensive measures to compensate for the shortcomings of a single treatment. In this study, ozone autohemo-therapy combined with pharmacological therapy was used to treat PHN, and results showed that this combination treatment resulted in more significant improvements compared with pharmacological therapy alone in the VAS, MPQ, PGIC, and WHOQOL-BREF scores and in 50% VAS reduction of the initial value after treatment, which could improve pain symptoms and quality of life. In addition, ozone auto-hemotherapy combined with pharmacological therapy did not increase adverse reactions after treatment. Therefore, ozone autohemotherapy combined with pharmacological therapy was superior to isolated pharmacological therapy in the treatment of PHN and was an effective and safe way to relieve PHN.

Some studies have reported that PHN is related to several mechanisms. For example, PHN is a peripheral neuropathy, primarily presented as peripheral nerve inflammation and abnormal conduction after nerve injury. The anatomy of the primary afferent receptor is complete; however, the state is kept as abnormally hyperactive, which plays an important role in causing pain and maintaining abnormal pain[@b25-jpr-11-1637]; this can be described as an "irritant receptor." In addition, PHN is described as a central nervous system (CNS) abnormality (CNS sensitization), and abnormal pain and generalized C fibrosis are present at the same time; the completed and low-threshold A² fiber enters into the superficial layer of the dorsal horn of the spinal cord, directly connected with the two-stage pain-transmitting neuron, causing the pain.[@b26-jpr-11-1637],[@b27-jpr-11-1637] Moreover, for PHN, in the areas with obvious sensory deficits but no abnormal pain, there is persistent pain, or loss of sensory pain, which can be described as "afferent nerve block."[@b28-jpr-11-1637] Finally, some studies have also shown that PHN is related to mental factors, as stress and anxiety can also lead to PHN.[@b29-jpr-11-1637]

Although there are many methods of treating PHN with comprehensive measures, there are few clinical studies on this method. Ozone autohemotherapy has been a basic and clinical study for nearly 40 years and has become a relatively mature method of clinical treatment. Nowadays, ozone auto-hemotherapy is reported as being mainly used for the therapy of viral hepatitis, hyperlipidemia, stroke, rheumatic diseases, insomnia, and cancer. However, the effect of ozone autohemo-therapy on PHN remains unclear. In this study, ozone auto-hemotherapy was used to treat PHN, and an obvious clinical effect was achieved. The reasons for this clinical effect may be related to the following mechanisms: 1) Medical ozone has a strong bactericidal effect, and specific concentration of medical ozone can inhibit the growth and reproduction of herpes virus and promote the phagocytosis of leukocytes for herpes virus;[@b30-jpr-11-1637],[@b31-jpr-11-1637] 2) medical ozone can increase the oxygen-carrying ability and erythrocyte rheology of red blood cells, increase the oxygen supply for tissues and cells, improve the microcirculation in damaged nerve and skin tissue, and promote the repair of local nerves and tissue;[@b32-jpr-11-1637] 3) medical ozone mixed with blood can produce hydrogen peroxide (H~2~O~2~), which can be as an important messenger, activate the body's immune system, initiate a series of chemical reactions, induce the production of interleukin and interferon and other cytokines to activate and regulate the immune system function, and, finally, restore the normal functioning of the thalamus for the pain loop;[@b33-jpr-11-1637] 4) ozone autohemotherapy can bring a pleasant sensation to the person, relieve the patient's fatigue and depression, and improve physical strength and mental stability.[@b34-jpr-11-1637] In addition, reactive oxygen species (ROS) and lipid oxidative products (LOPs), believed to be involved in the biological progress of ozone, are produced immediately after ozone is dissolved in biological water (plasma, lymph, urine, interstitial fluid, etc.).[@b20-jpr-11-1637] ROS and LOPs have been reported to activate nuclear transcriptional factors, such as nuclear factor-erythroid 2--related factor 2, so as to alleviate pain.[@b35-jpr-11-1637],[@b36-jpr-11-1637] Finally, one study also speculated that ozone directly or indirectly acted on transmembrane proteins, intracellular cascades, and nuclear transcriptions to alleviate pain.[@b37-jpr-11-1637] Therefore, this clinical effect of ozone autohemotherapy in PHN is a complicated process, and its specific mechanisms require further study.

In conclusion, the findings of this study demonstrated that ozone autohemotherapy combined with pharmacological therapy was superior to isolated pharmacological therapy in the treatment of PHN and was an effective and safe way to relieve PHN.

**Disclosure**

The authors report no conflicts of interest in this work.

![Flowchart of this study.\
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###### 

Characteristics of both groups at baseline

  Characteristic                                                                  P group (n=45)   O group (n=46)   *P*-value
  ------------------------------------------------------------------------------- ---------------- ---------------- -----------
  Age (years)[a](#tfn2-jpr-11-1637){ref-type="table-fn"}                          62.3±11.2        63.6±10.5        0.567
  Gender[b](#tfn3-jpr-11-1637){ref-type="table-fn"}                               25/20            28/18            0.457
  Weight (kg)[a](#tfn2-jpr-11-1637){ref-type="table-fn"}                          58.4±8.5         59.2±9.4         0.854
  Herpes zoster site                                                                                                
  Intercostal region                                                              30               35               0.834
  Neck and arm region                                                             3                5                0.823
  Face region                                                                     8                6                0.754
  Lumbosacral region                                                              4                5                0.678
  Duration of PHN (months)[a](#tfn2-jpr-11-1637){ref-type="table-fn"}             2.8±1.5          2.9±1.6          0.821
  Cardiac disease[b](#tfn3-jpr-11-1637){ref-type="table-fn"}                      24/45            25/46            0.659
  Pulmonary disease[b](#tfn3-jpr-11-1637){ref-type="table-fn"}                    26/45            24/46            0.547
  Liver and renal diseases[b](#tfn3-jpr-11-1637){ref-type="table-fn"}             8/45             8/46             0.625
  Metabolism and nutrition disorders[b](#tfn3-jpr-11-1637){ref-type="table-fn"}   6/45             7/46             0.689

**Notes:** Data are presented as mean ± SD or n. P group = pharmacological therapy group; O group = ozone therapy group. *P*\<0.05 was considered statistically significant.

Independent-samples *t*-test.

Chi-square test.

**Abbreviation:** PHN, postherpetic neuralgia.

###### 

VAS scores of both groups before and after treatment

  Group            Before    1 week after                                         1 month after                                                                                    3 months after
  ---------------- --------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------
  P group (n=45)   6.2±1.3   5.0±1.2[a](#tfn6-jpr-11-1637){ref-type="table-fn"}   3.1±1.1[a](#tfn6-jpr-11-1637){ref-type="table-fn"}                                               1.8±0.8[a](#tfn6-jpr-11-1637){ref-type="table-fn"}
  O group (n=46)   6.5±1.4   4.8±1.1[a](#tfn6-jpr-11-1637){ref-type="table-fn"}   1.8±1.1[a](#tfn6-jpr-11-1637){ref-type="table-fn"},[b](#tfn7-jpr-11-1637){ref-type="table-fn"}   0.9±0.5[a](#tfn6-jpr-11-1637){ref-type="table-fn"},[b](#tfn7-jpr-11-1637){ref-type="table-fn"}

**Notes:** Data are presented as mean ± SD. P group = pharmacological therapy group; O group = ozone therapy group. *P*\<0.05 was considered statistically significant.

Repeated-measures ANOVA test, *P*\<0.05.

Independent-samples *t*-test, *P*\<0.05.

**Abbreviation:** VAS, Visual Analog Scale.

###### 

VAS reduction of 50% of the initial value in both groups after treatment

  Group            Before   1 week after   1 month after                                    3 months after
  ---------------- -------- -------------- ------------------------------------------------ ----------------
  P group (n=45)   0        8              26                                               40
  O group (n=46)   0        13             41[a](#tfn10-jpr-11-1637){ref-type="table-fn"}   43

**Notes:** Data are presented as n. P group = pharmacological therapy group; O group = ozone therapy group. *P*\<0.05 was considered statistically significant.

Chi-squared test, *P*\<0.05.

**Abbreviation:** VAS, Visual Analog Scale.

###### 

SF-MPQ score of both groups before and after treatment

  SF-MPQ            P group (n=45)   O group (n=46)                                                                                                                                                                                                                                                                                                                             
  ----------------- ---------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------ ---------- ------------------------------------------------------ --------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  Sensory score     5.7±0.8          4.6±0.7[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    3.7±0.5[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    2.8±0.6[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    5.7±0.8    4.4±0.5[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    2.6±0.4[a](#tfn13-jpr-11-1637){ref-type="table-fn"},[b](#tfn14-jpr-11-1637){ref-type="table-fn"}    1.6±0.5[a](#tfn13-jpr-11-1637){ref-type="table-fn"},[b](#tfn14-jpr-11-1637){ref-type="table-fn"}
  Effective score   4.2±1.0          3.2±0.9[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    2.9±0.9[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    1.8±0.8[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    4.3±0.9    3.0±0.8[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    1.5±0.6[a](#tfn13-jpr-11-1637){ref-type="table-fn"},[b](#tfn14-jpr-11-1637){ref-type="table-fn"}    0.9±0.5[a](#tfn13-jpr-11-1637){ref-type="table-fn"},[b](#tfn14-jpr-11-1637){ref-type="table-fn"}
  Total score       9.1±1.1          7.5±1.0[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    6.2±0.9[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    4.5±0.7[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    9.1±1.1    7.4±0.9[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    4.3±0.8[a](#tfn13-jpr-11-1637){ref-type="table-fn"},[b](#tfn14-jpr-11-1637){ref-type="table-fn"}    2.5±0.5[a](#tfn13-jpr-11-1637){ref-type="table-fn"},[b](#tfn14-jpr-11-1637){ref-type="table-fn"}
  VAS (mm)          68.2±7.2         52.4±6.5[a](#tfn13-jpr-11-1637){ref-type="table-fn"}   32.5±5.2[a](#tfn13-jpr-11-1637){ref-type="table-fn"}   18.3±4.5[a](#tfn13-jpr-11-1637){ref-type="table-fn"}   65.3±8.1   47.2±5.6[a](#tfn13-jpr-11-1637){ref-type="table-fn"}   19.2±5.2[a](#tfn13-jpr-11-1637){ref-type="table-fn"},[b](#tfn14-jpr-11-1637){ref-type="table-fn"}   9.4±3.2^\#^
  PPI               4.5±0.9          3.4±0.7[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    2.5±0.6[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    1.7±0.7[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    4.6±0.8    3.2±0.8[a](#tfn13-jpr-11-1637){ref-type="table-fn"}    1.8±0.6[a](#tfn13-jpr-11-1637){ref-type="table-fn"},[b](#tfn14-jpr-11-1637){ref-type="table-fn"}    0.8±0.5^\*\#^

**Notes:** Data are presented as mean ± SD. P group = pharmacological therapy group; O group = ozone therapy group; T0= before treatment; T1=1 week after treatment; T2=1 month after treatment; T1=3 months after treatment. *P*\<0.05 was considered statistically significant.

Repeated-measures ANOVA test, *P*\<0.05.

Independent-samples *t*-test, compared with P group, *P*\<0.05.

**Abbreviations:** MPQ, McGill Pain Questionnaire; VAS, Visual Analog Scale; PPI, present pain intensity.

###### 

PGIC score of both groups before and after treatment

  Group            Before   1 week after   1 month after                                                                                      3 months after
  ---------------- -------- -------------- -------------------------------------------------------------------------------------------------- -----------------------------------------------------
  P group (n=45)   --       3.2±0.8        2.4±0.9[a](#tfn17-jpr-11-1637){ref-type="table-fn"}                                                1.2±0.7[a](#tfn17-jpr-11-1637){ref-type="table-fn"}
  O group (n=46)   --       3.1±0.7        1.6±0.8[a](#tfn17-jpr-11-1637){ref-type="table-fn"},[b](#tfn18-jpr-11-1637){ref-type="table-fn"}   0.7±0.4

**Notes:** Data are presented as mean ± SD. P group = pharmacological therapy group; O group = ozone therapy group. *P*\<0.05 was considered statistically significant.

Repeated-measures ANOVA test, *P*\<0.05.

Independent-samples *t*-test, *P*\<0.05.

**Abbreviation:** PGIC, Patients' Global Impression of Change.

###### 

WHOQOL-BREF score of both groups before and after treatment

  Group            Before    1 week after                                          1 month after                                                                                      3 months after
  ---------------- --------- ----------------------------------------------------- -------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  P group (n=45)   0.8±0.6   1.5±0.7[a](#tfn21-jpr-11-1637){ref-type="table-fn"}   2.8±0.5[a](#tfn21-jpr-11-1637){ref-type="table-fn"}                                                3.6±0.4[a](#tfn21-jpr-11-1637){ref-type="table-fn"}
  O group (n=46)   0.9±0.5   1.8±0.6[a](#tfn21-jpr-11-1637){ref-type="table-fn"}   3.4±0.6[a](#tfn21-jpr-11-1637){ref-type="table-fn"},[b](#tfn22-jpr-11-1637){ref-type="table-fn"}   4.2±0.5[a](#tfn21-jpr-11-1637){ref-type="table-fn"},[b](#tfn22-jpr-11-1637){ref-type="table-fn"}

**Notes:** Data are presented as the mean ± SD. P group = pharmacological therapy group; O group = ozone therapy group. *P*\<0.05 was considered statistically significant.

Repeated-measures ANOVA test, *P*\<0.05.

Independent-samples *t*-test, *P*\<0.05.

**Abbreviation:** WHOQOL, World Health Organization Quality of Life.

###### 

Adverse reactions observed in both groups after treatment

  Adverse reaction                                              P group (n=45)   O group (n=46)   *P*-value
  ------------------------------------------------------------- ---------------- ---------------- -----------
  Nausea[a](#tfn25-jpr-11-1637){ref-type="table-fn"}            4/45             5/46             0.954
  Vomiting[a](#tfn25-jpr-11-1637){ref-type="table-fn"}          2/45             2/46             0.869
  Dizziness[a](#tfn25-jpr-11-1637){ref-type="table-fn"}         3/45             4/46             0.872
  Somnolence[a](#tfn25-jpr-11-1637){ref-type="table-fn"}        4/45             5/46             1.000
  Palpitation[a](#tfn25-jpr-11-1637){ref-type="table-fn"}       2/45             3/46             0.925
  Chest tightness[a](#tfn25-jpr-11-1637){ref-type="table-fn"}   3/45             4/46             0.872
  Bleeding[a](#tfn25-jpr-11-1637){ref-type="table-fn"}          0/46             0/46             1.000
  Infection[a](#tfn25-jpr-11-1637){ref-type="table-fn"}         2/45             1/46             0.925
  Allergy[a](#tfn25-jpr-11-1637){ref-type="table-fn"}           1/45             1/46             0.936

**Notes:** Data are presented as n. P group = pharmacological therapy group; O group = ozone therapy group. *P*\<0.05 was considered statistically significant.

Chi-square test.

[^1]: These authors contributed equally to this work
